This Data Management and Biostatistics Core will support and strengthen projects on the chemotherapy, immunology, and ecology of leishmaniasis. As a randomized clinical trial, the chemotherapy project has more stringent requirements in terms of data management and analysis, so receives greater emphasis. The general objective is to ensure that the data management and biostatistics capacities of CIDEIM (the Major Foreign Collaborator) reach high international standards, and are sustainable. Relative to biostatistics, the current data management capacity is lower, so requires more strengthening. In order to reach the general objective, we have set five specific aims, and planned the following activities. 1) To attain the required standards of accuracy and security in the data management of the proposed projects. We will develop custom data management systems using the TrialDB package developed in Yale, 2) To enable CIDEIM to sustain these standards for future projects. CIDEIM personnel will be trained in TrialDB, and will run the custom systems when they have been transferred from Yale to CIDEIM. 3) To attain the required standards in statistical aspects of design, planning and execution of the proposed intervention trial. Experienced statisticians at CIDEIM and Yale have, together with the trial investigators, constructed the trial design to give adequate statistical power; to minimize bias; and, by means of a planned interim analysis, to allow for early stopping. 4) To devise and implement a Data and Safety Monitoring Plan, and convene a Data Safety and Monitoring Board (DSMB). Although the trial is Phase II, rather than III, due to the multisite nature of the trial, and inclusion of children, we have decided to convene a DSMB to monitor progress and advise the investigators. 5) To devise and execute a plan for statistical analysis of the trial. The trial has a well defined binary endpoint, and the planned analysis will yields valid statistical inference, taking into account factors such as the prior interim analysis, and the possible need to use exact, rather than asymptotic, logistic regression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI065866-02
Application #
7310347
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
2
Fiscal Year
2006
Total Cost
$149,869
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Obonaga, Ricardo; Fernández, Olga Lucía; Valderrama, Liliana et al. (2014) Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. Antimicrob Agents Chemother 58:144-52
Carrasquilla, María C; Munstermann, Leonard; Marín, Dairo et al. (2012) Description of Lutzomyia (Helcocyrtomyia) tolimensis, a new species of phlebotomine sandfly (Diptera: Psychodidae) from Colombia. Mem Inst Oswaldo Cruz 107:993-7
Cohnstaedt, Lee W; Caceres, Abraham G; Beati, Lorenza et al. (2012) The population structure of Lutzomyia verrucarum (Diptera: Psycodidae), a Bartonella bacilliformis and Leishmania peruviana vector in Peru. J Med Entomol 49:77-84
Fernández, Olga; Diaz-Toro, Yira; Valderrama, Liliana et al. (2012) Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp. J Clin Microbiol 50:2207-11
Rubiano, Luisa Consuelo; Miranda, María Consuelo; Muvdi Arenas, Sandra et al. (2012) Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 205:684-92
Rodriguez-Pinto, Daniel; Navas, Adriana; Blanco, Víctor Manuel et al. (2012) Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by Leishmania (Viannia) species. PLoS Negl Trop Dis 6:e1627
Ramírez, Carolina; Díaz-Toro, Yira; Tellez, Jair et al. (2012) Human macrophage response to L. (Viannia) panamensis: microarray evidence for an early inflammatory response. PLoS Negl Trop Dis 6:e1866
Ocampo, C B; Ferro, M C; Cadena, H et al. (2012) Environmental factors associated with American cutaneous leishmaniasis in a new Andean focus in Colombia. Trop Med Int Health 17:1309-17
Jayakumar, Asha; Castilho, Tiago M; Park, Esther et al. (2011) TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia). PLoS Negl Trop Dis 5:e1204
Gallego, Carolina; Golenbock, Douglas; Gomez, Maria Adelaida et al. (2011) Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis. Infect Immun 79:2871-9

Showing the most recent 10 out of 23 publications